Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7131171 | 0.88 | EGFR (0.55) | RAB9ANPC1GAAHTTEGFR | |
| SCHEMBL3220194 | 0.85 | RAB9A (0.54) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL27803739 | 0.82 | NPC1 (0.50) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL4487889 | 0.81 | TAS1R3 (0.55) | RAB9ANPC1ALDH1A1MAPK1HTT | |
| SCHEMBL6830891 | 0.80 | EGFR (0.44) | SMN1; SMN2RAB9ANPC1GAAEGFR | |
| SCHEMBL11557801 | 0.77 | EGFR (0.56) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL30421262 | 0.77 | NFKB1 (0.61) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL28557381 | 0.77 | NFKB1 (0.61) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL27803821 | 0.76 | BRAF (0.51) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL14469060 | 0.76 | EGFR (0.57) | SMN1; SMN2ALDH1A1GAAMAPK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | UCB SA (GB) | 2010-03-11 | — | — | US | disclosed |
| US-7141590-B2 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | UCB SA (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | DARWIN DISCOVERY LIMITED (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030004189-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | DARWIN DISCOVERY LTD. (GB) | 2003-01-02 | — | — | US | disclosed |
| WO-2002053544-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | DARWIN DISCOVERY LTD. (GB) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | NNT, NAPRT, NNMT | SMN1; SMN2 976/4885RAB9A 1926/4885NPC1 394/4885 |
| US-20030004189-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | NNT, NAPRT, NNMT | SMN1; SMN2 976/4885RAB9A 1926/4885NPC1 394/4885 |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | NNT, NAPRT, NNMT | SMN1; SMN2 976/4885RAB9A 1926/4885NPC1 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.